Table 2.
Association between CYP1B1 expression and clinicopathologic features.
| Characteristic | CYP1B1-positive n = 160 (76.9%) | CYP1B1-negative n = 48 (23.1%) | P value |
|---|---|---|---|
| Gender | 0.223 | ||
| Male (n = 166, 79.8%) | 131 (78.9%) | 35 (21.1%) | |
| Female (n = 42, 20.2%) | 36 (85.7%) | 6 (14.3%) | |
| Histological type | 0.002 | ||
| Urothelial carcinoma (n = 160, 76.9%) | 130 (81.2%) | 30 (18.8%) | |
| Squamous cell carcinoma (n = 16, 7.7%) | 14 (87.5%) | 2 (12.5%) | |
| Mucinous adenocarcinoma (n = 9, 4.3%) | 8 (88.9%) | 1 (11.1%) | |
| Papillary adenocarcinoma (n = 7, 3.4%) | 5 (71.4%) | 2 (28.6%) | |
| Normal (n = 16, 7.7%) | 3 (18.7%) | 13 (81.3%) | |
| Histological grade | |||
| I (n = 67, 34.4%) | 53 (79.1%) | 14 (20.9%) | 0.003 |
| II (n = 81, 42.7%) | 68 (84.0%) | 13 (16%) | |
| III (n = 44, 22.9%) | 36 (81.8%) | 8 (18.2%) | |
| Normal (n = 16, 7.7%) | 3 (18.7%) | 13 (81.3%) | |
| Histological stage | |||
| 1 (n = 53, 27.6%) | 45 (84.9%) | 8 (15.1%) | 0.002 |
| 2 (n = 101, 52.6%) | 74 (73.3%) | 27 (26.7%) | |
| 3 (n = 34, 17.7%) | 34 (100%) | 0 (0%) | |
| 4 (n = 4, 2.1%) | 4 (100%) | 0 (0%) | |
| Normal (n = 16, 7.7%) | 3 (18.7%) | 13 (81.3%) | |
| TNM staging | 0.011 | ||
| T1N0M0 (n = 54, 28.1%) | 47 (85.5%) | 11 (14.5%) | |
| T2N0M0 (n = 101, 52.6%) | 74 (73.3%) | 27 (26.7%) | |
| T3N0M0 (n = 34, 17.7%) | 34 (100%) | 0 (0%) | |
| T3N1M0 (n = 2, 1.0%) | 2 (100%) | 0 (0%) | |
| T3N2M0 (n = 1, 0.5%) | 1 (100%) | 0 (0%) | |
| Normal (n = 16, 7.7%) | 3 (18.7%) | 13 (81.3%) | |